drugset / Trial / NCT02448537
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Phase 2
Completed
42 enrolled
Massachusetts General Hospital
Dana-Farber Cancer Institute · collabPharmaMar · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.
Timeline
- Start
- 2015-08
- Primary completion
- 2017-02
- Completion
- 2019-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Lurbinectedin | Other / unclassified | — | Intravenous |